Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Valneva se - You Need To See This

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

U.S. Markets Open Higher; Jobless Claims Drop To 229,000

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Thursday.

Benzinga

Why Shares Of Valneva SE Are Soaring Today

Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

EU Says Final Decision Yet To Be Taken On Terminating Valneva COVID-19 Vaccine Deal

The European Commission said that no final decision had been made about the possible termination of a contract with Valneva SE (NASDAQ: VALN) to supply its COVID-19 vaccine to the European Union.

Benzinga

Why Valneva's Shares Are Plunging Today Premarket

Valneva SE (NASDAQ:VALN) warned it might have to reconsider its FY22 financial guidance after the European Commission informed the company of its intent to terminate an advance purchase agreement (APA) for its VLA2001 COVID-19 candidate vaccine. In November, the company signed the APA with the European Commission to supply up to 60 million doses of…

Benzinga

Valneva - Pfizer Post Encouraging Data From Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ:VALN) and Pfizer Inc (NYSE:PFE) have reported Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. In pediatric participants (5-17 years old) who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested. These…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years. The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards. Read Next: Why Did Moderna Recall Thousands Of COVID-19…

Benzinga

European Recommendation On Valneva's COVID-19 Shot Pushed Into April

Valneva SE (NASDAQ:VALN) now expects a positive recommendation from the European Medicines Agency (EMA) for its VLA2001 COVID-19 candidate vaccine in April. Earlier, the Company expected the European recommendation by the end of March. As announced in February, Valneva received a list of questions as part of the CHMP's initial assessment, to which…

Benzinga

Read Why Valneva's Stock Gained 7% Today

Valneva SE (NASDAQ:VALN) completed the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. Valneva posted topline results from the phase 3 trial in August last year. The primary endpoint result is mainly unchanged from that data drop. The removal of two subjects from the analysis increased the proportion of participants with protective…

Benzinga

Valneva Expects European Recommendation On COVID-19 Shot By March End

Valneva SE (NASDAQ: VALN) expects to start delivering its vaccine in Europe soon after it is recommended for conditional approval by the end of March.

Benzinga

Valneva Secures £20M From Scottish Enterprise For Vaccine Development

Valneva SE (NASDAQ: VALN) has been

Benzinga

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have

Benzinga

Why Are Valneva Shares Rising Today Premarket?

Valneva SE (NASDAQ: VALN) expects its COVID-19 vaccine candidate to boost its sales in FY22 considerably, after

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents

Valneva SE (NASDAQ: VALN) has

Benzinga

Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial

Valneva SE (NASDAQ: VALN) has

Benzinga

Why Valneva Shares Are Soaring Today

Valneva SE (NASDAQ: VALN) is trading significantly higher Wednesday following results from an initial laboratory study, which demonstrated that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001, neutralize the omicron variant.

Benzinga

Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows

Valneva SE (NASDAQ: VALN) has announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001,

Get all your
news in one place.

100's of premium titles.
One news app.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.